The direct thrombin inhibitor melagatran/ximelagatran

• Unit for Medication Outcomes Research and Education, University of Tasmania, Private Bag 26, Hobart, Tasmania 7001.

---

• 1. Brighton TA. The direct thrombin inhibitor melagatran/ximelagatran. Med J Aust 2004; 181: 432-437. <eMJA full text>
• 2. Controversial: oral thrombin inhibitor ximelagatran (exanta). Available at: www.arznei-telegramm.de/journal/j_0407_a.html (accessed Dec 2004).
• 3. US Food and Drug Administration: Statistical review and evaluation-clinical studies (Exanta 36 mg bid oral formulation). Available at: www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069b1.htm (accessed Dec 2004).
• 4. Australian Institute of Health and Welfare. Australian hospital statistics 2002–03. Available at: www.aihw.gov.au/publications/index.cfm/title/10015 (accessed Dec 2004).
• 5. SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor Ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-1698.
• 6. Stroke prevention using the oral direct thrombin inhibitor Ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V). Late-breaking clinical trial abstracts [abstract]. Circulation 2003; 108: 2723. Available at: http://circ.ahajournals.org/cgi/content/full/108/21/2723 (accessed Feb 2005)
• 7. Dewey HM, Thrift AG, Mihalopoulos C, et al. Lifetime cost of stroke subtypes in Australia: findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003; 34: 2502-2507.